BioLine RX Ltd ADR sell nvestor
Start price
30.09.23
/
50%
€1.64
Target price
30.09.24
€1.00
Performance (%)
-9.76%
End price
14.10.23
€1.48
Summary
This prediction ended on 14.10.23 with a price of €1.48. With a performance of -9.76%, the SELL prediction for BioLine RX Ltd ADR by nvestor was down slightly. nvestor has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
BioLine RX Ltd ADR | - | - |
iShares Core DAX® | 1.665% | 0.362% |
iShares Nasdaq 100 | -0.475% | -3.195% |
iShares Nikkei 225® | 2.620% | 1.174% |
iShares S&P 500 | -0.091% | -1.597% |
According to nvestor what are the pros and cons of BioLine RX Ltd ADR for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
Below average Management
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Business model of the past or high risk
Lower EBIT Margin than peer group
Increased challenges to pay loans and raise capital
Bad culture
Little innovation
Few uniques
Significant cyclical dependencies
Little known brand
Low dividend yield expected
ROE lower than 10% per year
Dependend from some customers or products
Comments by nvestor for this prediction
In the thread BioLine RX Ltd ADR diskutieren
Sell mit Kursziel 1,0
In the thread Trading BioLine RX Ltd ADR
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by nvestor for BioLine RX Ltd ADR
BioLine RX Ltd ADR
Start price
Target price
Perf. (%)
€2.14
09.09.23
09.09.23
€3.00
09.09.24
09.09.24
-18.69%
16.09.23
16.09.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
BioLine RX Ltd ADR
Start price
Target price
Perf. (%)
€1.77
31.10.20
31.10.20
€0.000
04.11.21
04.11.21
4.52%
14.11.20
14.11.20
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation